静滴阿奇霉素、白霉素、红霉素治疗小儿肺炎支原体急性期感染的疗效分析

Therapeutic efficacies of intravenous azithromycin,kitasamycin and erythromycin on treating children's acute infection caused by mycoplasma pneumonia

目的:比较静滴阿奇霉素、白霉素与红霉素治疗小儿肺炎支原体(MP)感染的疗效及药物不良反应。方法:选择确诊为MP急性期感染的患儿146例,随机分为3组,分别静滴上述三种药物,对它们的临床疗效及药物不良反应进行评价。结果:上述三种药物的疗效无显著性差异(P>0.05),药物不良反应发生率红霉素为50%,与其它两组相比差异显著(P<0.01);白霉素与阿奇霉素组药物不良反应发生率低,两组间对比无显著性差异(P>0.01)。结论:静滴阿奇霉素和白霉素疗效良好,药物不良反应少,可作为MP急性期感染的基础治疗药物,值得临床推广,其中白霉素为第一线抗生素,且价廉,可作为患儿MP急性期感染治疗的首选。

Objective： To compare the effects and adverse reactions of intravenous azithromyein （AT）, kitasamyein （KT） and erythromyein （ET） in treating children＇s infection caused by myeoplasma pneumonia （MP）. Methods： 146 eases of children with MP infection during acute stage were randomly divided into three groups. They were given intravenously AT, KT and ET respectively. Therapeutic effieaeies and adverse reactions among three kinds of drugs were evaluated. Results： There was not any significant difference in therapeutic effieaey among these three drugs （P 〉 0.05）. The adverse reaction rate of ET group was 50%, higher than the other groups （P 〈 0.01 ）. There was＇ t significant difference between AT group and KT group in adverse reactions （P 〉 0.01 ）. Conclusions： Intravenous AT and KT are effective and have less adverse reactions. Both of them are worth populzrizing as the basic medicine in treating children＇ s acute MP infection. KT as the front line antibiotic is the first selection in treating acute MP infection.